|
|
 | | | |
- close
- close
- close
- close
QUOTE AND NEWS
StreetInsider.com
May 21
Comment
The following is a list of notable articles to help get you through the lunch hour:
Facebook (FB) IPO Fail Leaves Retail Investors Holding the Bag...Again -> Read this!
Facebook Investors: Welcome Back to Apple! -> Read this!
Regulators...
Business Wire
May 7
Comment
Affymax, Inc. (Nasdaq: AFFY) today reported financial results for the first quarter ended March 31, 2012. The net income for the first quarter of 2012 was $31.5 million (or $0.87 per share) compared to a net loss of $9.6 million (or $(0.36) per
Market Intelligence Center
May 7
Comment
Affymax Inc (NASDAQ: AFFY) closed Friday's trading session at $12.58. In the past year, the stock has hit a 52-week low of $3.93 and 52-week high of $16.25. Affymax Inc (AFFY) stock has been showing support around $12.24 and resistance in the...
Business Wire
May 4
Comment
Affymax, Inc. (Nasdaq:AFFY) today announced the company's participation in the following investor conferences during the month of May. Deutsche Bank 37th Annual Health Care ConferenceWednesday, May 9, 201210:40 a.m. Eastern Time (7:40 a.m. Pacific
Market Intelligence Center
May 1
Comment
Affymax Inc (NASDAQ: AFFY) closed Monday's trading session at $13.11. In the past year, the stock has hit a 52-week low of $3.93 and 52-week high of $16.25. Affymax Inc (AFFY) stock has been showing support around $12.81 and resistance in the...
Business Wire
Apr 30
Comment
Affymax, Inc. (Nasdaq: AFFY) today announced that it will host a teleconference and webcast with management to provide a general business overview, as well as to discuss its first quarter 2012 financial results on Monday, May 7, 2012, at 4:30 p.m.
Market Intelligence Center
Apr 25
Comment
Affymax Inc (NASDAQ:AFFY) closed Tuesday's unsure trading session at $12.95. In the past year, the stock has hit a 52-week low of $3.93 and 52-week high of $16.25. Affymax Inc (AFFY) stock has been showing support around $11.14 and resistance in...
Business Wire
Apr 24
Comment
Affymax, Inc. (NASDAQ:AFFY) and Takeda Pharmaceutical Company Limited (TSE:4502), today announced that OMONTYS® (peginesatide) Injection is now available only for use in treating anemia due to chronic kidney disease (CKD) in adult patients on
Business Wire
Apr 13
Comment
Affymax, Inc. (Nasdaq:AFFY) and Takeda Pharmaceuticals U.S.A. (TPUSA) today announced that the Centers for Medicare and Medicaid Services (CMS) has granted a unique product reimbursement code, or Q-code, for OMONTYS® (peginesatide) Injection. The
FierceBiotech
Apr 10
Comment
Affymax ($AFFY) has banked a $50 million check from its partner Takeda Pharmaceutical after they won FDA approval for peginesatide, an anemia treatment that will now compete with Amgen ($AMGN) for market share. The biotech will co-promote the...
Suggest other news sources for this topic
more ▼WIKI ANALYSIS
WIKI ANALYSIS
 |
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article. |
References
| |||||||
